Developer docs
API playgroundTry for free, no card

Search company profiles

Adcytherix

Full company profile

uuid0002axs

Namestring
Adcytherix
Legal namestring
Adcytherix SAS
Websiteurl
adcytherix.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Adcytherix SAS is a clinical-stage biopharmaceutical company incorporated in Marseille, France in June 2024, developing next-generation antibody-drug conjugates (ADCs) for high-unmet-need cancers, with particular focus on tumors resistant to current-generation ADC therapies. The company's core technology is the proprietary ADCX-Engine platform, which integrates approved and clinically validated cancer drugs as payloads with optimized state-of-the-art linker architectures and precision antibody engineering to enable ADCs with fine-tuned conjugation parameters, broader therapeutic windows, and improved resistance profiles. Its lead product candidate, ADCX-020, combines a stable linker with an exatecan-derived topoisomerase I inhibitor payload and entered a Phase 1a/b dose-escalation and expansion trial in patients with advanced solid tumors, with the first patient dosed in March 2026.

The company is pre-revenue and pursues a B2B enterprise partnering model: it explicitly courts licensing and co-development deals with top-tier biotech and pharma companies as well as academic researchers across novel payload chemistry, target validation, and clinical translation, with future revenue expected from licensing milestones, co-development agreements, royalties, and ultimately the sale of proprietary ADC therapeutics upon regulatory approval. It operates with subsidiaries in the United States and the Netherlands alongside its Marseille headquarters, and is backed by a syndicate of top-tier life science investors including Pontifax, Bpifrance, Kurma Partners, Andera Partners, Angelini Ventures, Pureos Bioventures, RA Capital Management, DawnBiopharma (KKR), Surveyor Capital, and aMoon, having raised approximately €135 million in cumulative funding across a 2024 seed and 2025 Series A round.

Short descriptiontext

Adcytherix is a clinical-stage French biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) through its proprietary ADCX-Engine platform, targeting cancers resistant to current-generation ADCs and serving enterprise pharma and biotech partners via licensing and co-development deals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMarseille, France
HQ citystring
Marseille
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug conjugates, oncology therapeutics, ADC development, targeted cancer therapy, biopharmaceutical pipeline
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product revenue (future)
TypeOne Time License
Description

Pre-revenue clinical-stage biopharma company. No commercial products yet. Future revenue expected from sale of proprietary ADC therapeutic products upon regulatory approval.

adcytherix.com
2Licensing and co-development deals
TypeLicensing Royalties
Description

The company is open to partnerships with top-level biotech and pharma companies and academic researchers for novel payload chemistry, target validation and clinical translation. Revenue anticipated from licensing deals, co-development agreements and milestone payments as products advance through clinical development.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Its core work centers on the proprietary ADCX-Engine platform, which combines clinically validated targets with innovative payloads derived from approved cancer drugs, optimized linker architectures and precision antibody engineering. The lead candidate ADCX-020 is in a Phase 1 trial in patients with advanced solid tumors, designed to overcome resistance to current-generation ADCs and broaden the therapeutic window.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First patient dosed in Phase 1 trial within less than two years of company inception (March 2026)
+1 more record
Product overview1 text field

Adcytherix is a clinical-stage biopharmaceutical company developing a portfolio of next-generation antibody-drug conjugates (ADCs) for treating high unmet need diseases, particularly cancer. The company's product strategy centers on two key offerings: (1) the ADCX-Engine, a proprietary technology platform enabling the development of differentiated ADCs using clinically validated payloads and advanced conjugation engineering; and (2) ADCX-020, the lead drug candidate currently in Phase 1 clinical development for advanced solid tumors. The company is advancing its pipeline to address resistance against current-generation ADCs and broaden the therapeutic window across multiple oncology indications.

Product and service2 records
1ADCX-Engine
CategoryADC technology platform
Description

The ADCX-Engine is Adcytherix's proprietary ADC design platform that integrates approved and clinically validated cancer drugs as payloads with optimized, state-of-the-art linker architectures and precision antibody engineering. It enables rational design of highly selective ADCs with fine-tuned conjugation parameters that extend beyond conventional payload classes, enhance stability, overcome resistance, and improve safety while achieving deeper, more durable anti-tumor responses.

2ADCX-020
CategoryLead ADC drug candidate
Description

ADCX-020 is Adcytherix's lead ADC drug candidate incorporating a stable linker and an exatecan-derived topoisomerase I inhibitor payload. Designed to address key limitations of earlier ADC products through optimized molecular design to support an improved therapeutic index and broader applicability across multiple tumor types, it is being evaluated in a Phase 1 study in patients with advanced solid tumors.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

One Biosciences received a PSCC BOOST grant from the Paris-Saclay Cancer Cluster to develop the first single-cell assay for ADC therapies in oncology, in collaboration with Adcytherix. The project combines Adcytherix's ADC development expertise with One Biosciences' AI-powered single-cell profiling technology to analyze tumor samples and identify cellular signatures associated with treatment response, supporting precision oncology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage ADC company with approved product Zynlonta and a pipeline of pyrrolobenzodiazepine-based ADCs for hematologic and solid tumors. Comparable as an ADC-focused oncology biotech with proprietary payload chemistry.

2Mythic Therapeutics
TypeEmerging player
Description

Clinical-stage ADC biotech developing next-generation antibody-drug conjugates for solid tumors using proprietary technology. Comparable as an emerging player in novel ADC design.

TypeDirect peer
Description

Clinical-stage oncology company developing immune-stimulating antibody-drug conjugates (ISACs). Comparable as a next-generation ADC biotech developing novel ADC mechanisms for solid tumors.

TypeDirect peer
Description

Germany-based clinical-stage ADC company leveraging proprietary amanitin payload chemistry (ATAC platform). Comparable as a European ADC platform company focusing on novel payload classes for cancer therapy.

TypeDirect peer
Description

Clinical-stage oncology biotech developing ADC and antibody-based therapeutics for solid tumors. Comparable as an ADC-focused biotech pursuing novel antibody-drug conjugate designs in oncology.

TypeDirect peer
Description

Germany-based clinical-stage biotech developing next-generation ADCs with proprietary payload and linker platforms (P5 conjugation, TOPi payloads). Highly comparable European ADC peer with similar platform-and-payload innovation strategy.

TypeDirect peer
Description

Clinical-stage biotech with a cell-free protein synthesis platform developing ADCs and other biologics. Comparable as a platform-based ADC developer with lead programs in solid tumor oncology.

TypeEmerging player
Description

Clinical-stage ADC company developing next-generation antibody-drug conjugates for solid tumors, recently acquired by Genmab. Comparable as an emerging ADC peer with novel payload and linker approaches.

TypeDirect peer
Description

Clinical-stage ADC biotech developing next-generation antibody-drug conjugates with proprietary payload and linker platforms (e.g., Dolasynthen, Immunosynthen). Closely comparable as a platform-driven ADC company targeting solid tumors with novel conjugation chemistry.

TypeBroad incumbent
Description

Global pharmaceutical company and ADC market leader through Enhertu (DXd ADC platform) jointly developed with AstraZeneca. Comparable as a broad incumbent that defines the competitive standard in the ADC space Adcytherix is targeting.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adcytherix

Oncology Biopharmaceuticalsadcytherix.com

Adcytherix is a clinical-stage French biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) through its proprietary ADCX-Engine platform, targeting cancers resistant to current-generation ADCs and serving enterprise pharma and biotech partners via licensing and co-development deals.

What Adcytherix does

Adcytherix SAS is a clinical-stage biopharmaceutical company incorporated in Marseille, France in June 2024, developing next-generation antibody-drug conjugates (ADCs) for high-unmet-need cancers, with particular focus on tumors resistant to current-generation ADC therapies. The company's core technology is the proprietary ADCX-Engine platform, which integrates approved and clinically validated cancer drugs as payloads with optimized state-of-the-art linker architectures and precision antibody engineering to enable ADCs with fine-tuned conjugation parameters, broader therapeutic windows, and improved resistance profiles. Its lead product candidate, ADCX-020, combines a stable linker with an exatecan-derived topoisomerase I inhibitor payload and entered a Phase 1a/b dose-escalation and expansion trial in patients with advanced solid tumors, with the first patient dosed in March 2026.

The company is pre-revenue and pursues a B2B enterprise partnering model: it explicitly courts licensing and co-development deals with top-tier biotech and pharma companies as well as academic researchers across novel payload chemistry, target validation, and clinical translation, with future revenue expected from licensing milestones, co-development agreements, royalties, and ultimately the sale of proprietary ADC therapeutics upon regulatory approval. It operates with subsidiaries in the United States and the Netherlands alongside its Marseille headquarters, and is backed by a syndicate of top-tier life science investors including Pontifax, Bpifrance, Kurma Partners, Andera Partners, Angelini Ventures, Pureos Bioventures, RA Capital Management, DawnBiopharma (KKR), Surveyor Capital, and aMoon, having raised approximately €135 million in cumulative funding across a 2024 seed and 2025 Series A round.

Adcytherix firmographics

Firmographics
Name
Adcytherix
Legal name
Adcytherix SAS
Website
https://adcytherix.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Adcytherix is a clinical-stage French biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) through its proprietary ADCX-Engine platform, targeting cancers resistant to current-generation ADCs and serving enterprise pharma and biotech partners via licensing and co-development deals.
Ownership category
akta.pro rank

Adcytherix industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody drug conjugates
  • Oncology therapeutics
  • ADC development
  • Targeted cancer therapy
  • Biopharmaceutical pipeline

Where Adcytherix is headquartered

Location

Headquarters

HQ city
Marseille
HQ country
France
HQ region
Europe

Offices4 records

Markets served

Adcytherix business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Product revenue (future): Pre-revenue clinical-stage biopharma company. No commercial products yet. Future revenue expected from sale of proprietary ADC therapeutic products upon regulatory approval.
  2. Licensing and co-development deals: The company is open to partnerships with top-level biotech and pharma companies and academic researchers for novel payload chemistry, target validation and clinical translation. Revenue anticipated from licensing deals, co-development agreements and milestone payments as products advance through clinical development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Adcytherix product offering

Product offering

Core offering

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Its core work centers on the proprietary ADCX-Engine platform, which combines clinically validated targets with innovative payloads derived from approved cancer drugs, optimized linker architectures and precision antibody engineering. The lead candidate ADCX-020 is in a Phase 1 trial in patients with advanced solid tumors, designed to overcome resistance to current-generation ADCs and broaden the therapeutic window.

Product overview

Adcytherix is a clinical-stage biopharmaceutical company developing a portfolio of next-generation antibody-drug conjugates (ADCs) for treating high unmet need diseases, particularly cancer. The company's product strategy centers on two key offerings: (1) the ADCX-Engine, a proprietary technology platform enabling the development of differentiated ADCs using clinically validated payloads and advanced conjugation engineering; and (2) ADCX-020, the lead drug candidate currently in Phase 1 clinical development for advanced solid tumors. The company is advancing its pipeline to address resistance against current-generation ADCs and broaden the therapeutic window across multiple oncology indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • ADCX-Engine The ADCX-Engine is Adcytherix's proprietary ADC design platform that integrates approved and clinically validated cancer drugs as payloads with optimized, state-of-the-art linker architectures and precision antibody engineering. It enables rational design of highly selective ADCs with fine-tuned conjugation parameters that extend beyond conventional payload classes, enhance stability, overcome resistance, and improve safety while achieving deeper, more durable anti-tumor responses.
  • ADCX-020 ADCX-020 is Adcytherix's lead ADC drug candidate incorporating a stable linker and an exatecan-derived topoisomerase I inhibitor payload. Designed to address key limitations of earlier ADC products through optimized molecular design to support an improved therapeutic index and broader applicability across multiple tumor types, it is being evaluated in a Phase 1 study in patients with advanced solid tumors.

Quantifiable outcome

  • First patient dosed in Phase 1 trial within less than two years of company inception (March 2026)
  • +1 more outcomes

Companies that use Adcytherix

Customer profile

Segments1 record

Ideal customer profiles3 records

Adcytherix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Adcytherix partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • One BiosciencesminorStrategic or Co-development Partner · 1 January 2026One Biosciences received a PSCC BOOST grant from the Paris-Saclay Cancer Cluster to develop the first single-cell assay for ADC therapies in oncology, in collaboration with Adcytherix. The project combines Adcytherix's ADC development expertise with One Biosciences' AI-powered single-cell profiling technology to analyze tumor samples and identify cellular signatures associated with treatment response, supporting precision oncology.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

Adcytherix competitors and assessment

Company assessment

Direct peers

  • ADC Therapeutics: Commercial-stage ADC company with approved product Zynlonta and a pipeline of pyrrolobenzodiazepine-based ADCs for hematologic and solid tumors. Comparable as an ADC-focused oncology biotech with proprietary payload chemistry.
  • Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody-drug conjugates (ISACs). Comparable as a next-generation ADC biotech developing novel ADC mechanisms for solid tumors.
  • Heidelberg Pharma: Germany-based clinical-stage ADC company leveraging proprietary amanitin payload chemistry (ATAC platform). Comparable as a European ADC platform company focusing on novel payload classes for cancer therapy.
  • Pyxis Oncology: Clinical-stage oncology biotech developing ADC and antibody-based therapeutics for solid tumors. Comparable as an ADC-focused biotech pursuing novel antibody-drug conjugate designs in oncology.
  • Tubulis: Germany-based clinical-stage biotech developing next-generation ADCs with proprietary payload and linker platforms (P5 conjugation, TOPi payloads). Highly comparable European ADC peer with similar platform-and-payload innovation strategy.
  • Sutro Biopharma: Clinical-stage biotech with a cell-free protein synthesis platform developing ADCs and other biologics. Comparable as a platform-based ADC developer with lead programs in solid tumor oncology.
  • Mersana Therapeutics: Clinical-stage ADC biotech developing next-generation antibody-drug conjugates with proprietary payload and linker platforms (e.g., Dolasynthen, Immunosynthen). Closely comparable as a platform-driven ADC company targeting solid tumors with novel conjugation chemistry.

Emerging players

  • Mythic Therapeutics: Clinical-stage ADC biotech developing next-generation antibody-drug conjugates for solid tumors using proprietary technology. Comparable as an emerging player in novel ADC design.
  • ProfoundBio: Clinical-stage ADC company developing next-generation antibody-drug conjugates for solid tumors, recently acquired by Genmab. Comparable as an emerging ADC peer with novel payload and linker approaches.

Broad incumbents

  • Daiichi Sankyo: Global pharmaceutical company and ADC market leader through Enhertu (DXd ADC platform) jointly developed with AstraZeneca. Comparable as a broad incumbent that defines the competitive standard in the ADC space Adcytherix is targeting.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Adcytherix social profiles

Digital presence

Adcytherix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adcytherix leadership team

Management profile

Number of profiles

Profiles11 records

Adcytherix subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Adcytherix funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adcytherix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adcytherix

What does Adcytherix do?

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Its core work centers on the proprietary ADCX-Engine platform, which combines clinically validated targets with innovative payloads derived from approved cancer drugs, optimized linker architectures and precision antibody engineering. The lead candidate ADCX-020 is in a Phase 1 trial in patients with advanced solid tumors, designed to overcome resistance to current-generation ADCs and broaden the therapeutic window.

Is Adcytherix a public or private company?

Adcytherix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Adcytherix founded?

Adcytherix was founded in 2024. It employs 11 to 50 people.

Where is Adcytherix based?

Adcytherix is headquartered in Marseille, France, in the Europe region.

How does Adcytherix make money?

Two revenue lines are on record. Product revenue (future) is the primary driver. The others are licensing and co-development deals.

Who are Adcytherix's main competitors?

Direct peers on record are ADC Therapeutics, Bolt Biotherapeutics, Heidelberg Pharma, Pyxis Oncology, Tubulis, Sutro Biopharma and Mersana Therapeutics. Emerging players are Mythic Therapeutics and ProfoundBio. Daiichi Sankyo is listed as a broad incumbent.

Does Adcytherix have an API?

No public API is recorded for Adcytherix.

What industry is Adcytherix in?

Adcytherix's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325413 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarOne Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC TherapiesOne Biosciences received a Paris-Saclay Cancer Cluster BOOST grant to develop the first single-cell assay for antibody-drug conjugate therapies. The project, in collaboration with Adcytherix, aims to improve patient selection and support companion diagnostics. The grant positions France at the forefront of precision oncology innovation.FierceBiotechKurma closes €215 Europe-focused fund to spread across 20 biotechsParis-based venture capital firm Kurma Partners has closed its Biofund IV at €215 million, falling 14% short of its €250 million target but growing 34% larger than its predecessor fund Biofund III. The fund will deploy capital across approximately 20 biotech investments, with current portfolio companies including obesity startup Alveus Therapeutics and antibody-drug conjugate developer Adcytherix. Cornerstone investors in the fund include Bpifrance, Australian biotech CSL, the European Investment Fund, and Kurma's parent company Eurazeo.Informa ConnectVenture Investors Shift Strategy Toward Refined Modalities, Women’s Health and Platform DisciplineVenture investors at the BIO-Europe Spring panel are recalibrating capital deployment toward proven modalities like antibody-drug conjugates (ADCs), underfunded disease areas such as fertility and women\u2019s health, and stricter development discipline for platform companies. Andera Partners highlighted continued investment in ADC refinement through companies like Adcytherix, while M Ventures pointed to its founding of ReproNovo, a $65 million Series A fertility company in May 2025. Panelists emphasized that broad technology promises without clear execution pathways no longer attract early-stage capital, signaling a structural rather than cyclical industry shift.GlobeNewswireAdcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of GrowthAdcytherix dosed the first patient in its Phase 1 trial of ADCX-020, an antibody-drug conjugate for advanced solid tumors. The company also appointed Paul Jackson as COO, Magali Gibou as Chief Regulatory & Quality Officer, and Simon Sturge as Independent Chairman. The milestone marks its transition to a clinical-stage company.Global VenturingAngelini in $175m deal with EIB to invest in European healthtech -Angelini Ventures and the European Investment Bank (EIB) have formed a €150m ($175m) partnership aimed at investing in European healthtech startups over the next six years. Both entities will contribute €75m each, focusing on funding between seven to ten biotech, medical technology, and digital health startups amidst a challenging funding environment. The first deal in this collaboration is for Adcytherix, a French startup developing treatments for cancer.Il Sole 24 OREBiotech and digital health: 150 million fund for EU start-upsThe European Investment Bank and Angelini Ventures, the corporate venture capital arm of Angelini Industries, signed a €150 million co-investment agreement to finance European start-ups in biotechnology and digital health, with each party committing €75 million over six years. The partnership, the EIB's first such agreement with a corporate venture capital firm in healthcare, aims to co-invest in seven to ten European start-ups and has already made its first investment in Adcytherix, a French biopharmaceutical company developing antibody-drug conjugates for cancer treatment.FierceBiotechEU teams up with Angelini to funnel €150M to European health startupsThe European Investment Bank (EIB) and Angelini Industries have launched a joint €150 million funding initiative to support healthcare startups across Europe over the next six years. The partners will co-invest in seven to ten companies, starting with a series B round for French biotech Adcytherix, as part of the EIB's broader TechEU innovation project.GlobeNewswireAdcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC PowerhouseAdcytherix SAS, a Marseille-based biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer therapy, announced the completion of its proprietary ADCX-Engine platform and two executive appointments: Jan H.M. Schellens as Chief Medical Officer and Jaime Arango as Chief Financial Officer. The company, which raised €105 million in Series A financing in 2025, has completed its R&D infrastructure buildout and is transitioning from early-stage development to execution, with plans to advance ADCX-020 into first-in-human studies. The new executives bring over 20 years of biopharma experience, including prior roles at major pharmaceutical companies and academic institutions.The French Tech JournalFrench Tech Funding Wire Oct 17: The Big $300M Deel Deal; Plus Adcytherix, Step Pharma, SCAP Hologram & More!France's private equity and venture capital markets demonstrated resilience in H1 2025, with €14.7 billion invested across 1,476 companies despite a 5% year-on-year decline, as investors adopted a more value-driven approach amid inflationary pressures. The week's standout funding was Deel's $300 million Series E at a $17.3 billion valuation (44% jump from 2022), led by Ribbit Capital alongside Andreessen Horowitz and Coatue, with French co-founder Alex Bouaziz retaining 25-30% stake and the company reporting $1 billion annualized revenue and 15-17% EBITDA margins. Across 16 French tech fundraises totaling approximately €225.3 million, biotech and life sciences dominated at 80% of capital deployed, with Adcytherix's €105 million Series A marking Europe's largest ADC-focused round in 2025.